Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / Common Stock, $0.0001 par value
-
Shares outstanding
-
170M
-
Number of holders
-
249
-
Total 13F shares, excl. options
-
146M
-
Shares change
-
-1.12M
-
Total reported value, excl. options
-
$3.55B
-
Value change
-
-$24.6M
-
Put/Call ratio
-
0.6
-
Number of buys
-
119
-
Number of sells
-
-100
-
Price
-
$24.22
Significant Holders of ACADIA PHARMACEUTICALS INC - Common Stock, $0.0001 par value (ACAD) as of Q1 2022
298 filings reported holding ACAD - ACADIA PHARMACEUTICALS INC - Common Stock, $0.0001 par value as of Q1 2022.
ACADIA PHARMACEUTICALS INC - Common Stock, $0.0001 par value (ACAD) has 249 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 146M shares
of 170M outstanding shares and own 86.07% of the company stock.
Largest 10 shareholders include BAKER BROS. ADVISORS LP (41.9M shares), FMR LLC (13.5M shares), VANGUARD GROUP INC (12.6M shares), BlackRock Inc. (9.97M shares), EcoR1 Capital, LLC (5.99M shares), STATE STREET CORP (5.06M shares), PRICE T ROWE ASSOCIATES INC /MD/ (4.98M shares), D. E. Shaw & Co., Inc. (4.55M shares), FIRST TRUST ADVISORS LP (2.33M shares), and JPMORGAN CHASE & CO (2.31M shares).
This table shows the top 249 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.